Source disclosure: February 26, 2026, 15:30 JST
Chordia Therapeutics Inc. [190A.T]
TOKYO, Feb 26 (Pulse News Wire) – Chordia Therapeutics Inc. (190A.T) announced the initiation of an expanded cohort study for its drug rogocekib based on recommendations from the U.S.
Safety evaluation committee overseeing its Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company confirmed meeting the criteria for efficacy and safety set forth in the investigational plan after administering the drug to 42 cases. Following review by the safety evaluation committee, the recommendation was made to proceed with the expansion phase. The expanded cohort will follow FDA’s Project Optimus guidance and consist of two stages: Initial Expansion (IE) and Additional Expansion (AE). The IE stage will enroll approximately 30 patients with AML and MDS to evaluate safety and efficacy across multiple dosing regimens.
Data analysis from the dose escalation phase will inform decisions on which doses to test further. In the subsequent AE stage, the results from the IE cohort will determine the optimal dosage and patient population for transitioning to the Phase 2 trial, expected to commence around mid-2027. Results from the dose escalation phase are planned for presentation at an international conference in mid-2026. Based in Fujisawa, Kanagawa Prefecture, Chordia Therapeutics focuses on developing cancer treatments, led by its pipeline candidate rogocekib (CTX-712), currently undergoing a Phase 1/2 trial in the United States. The company also develops several other therapeutic agents targeting various oncogenic pathways.
AI-translated content. 🟢 Confidence: High See terms • Original filing